Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.98 |
| ▸ | CNR1 | P21554 | 11/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.50 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.50 |
| ▸ | TRPV2 | Q9Y5S1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31103617 | 0.99 | CNR2 (1.00) | CNR2CNR1MEN1GAAKMT2A | |
| SCHEMBL4537590 | 0.99 | CNR2 (1.00) | CNR2CNR1MEN1GAAKMT2A | |
| SCHEMBL5090381 | 0.99 | CNR2 (1.00) | CNR2CNR1MEN1GAAKMT2A | |
| SCHEMBL16124349 | 0.96 | CNR2 (0.94) | CNR2CNR1MEN1GAAKMT2A | |
| SCHEMBL25981698 | 0.90 | CNR2 (0.80) | CNR2CNR1MEN1GAAKMT2A | |
| SCHEMBL11757291 | 0.89 | CNR2 (0.82) | CNR2CNR1MEN1GAAKMT2A | |
| SCHEMBL31545082 | 0.88 | CNR2 (0.81) | CNR2CNR1MEN1GAAKMT2A | |
| SCHEMBL22783274 | 0.87 | CNR2 (0.78) | CNR2CNR1MEN1GAAKMT2A | |
| SCHEMBL11599749 | 0.86 | CNR1 (0.73) | CNR2CNR1MEN1GAAKMT2A | |
| SCHEMBL11741078 | 0.86 | CNR2 (0.76) | CNR2CNR1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| EP-3664795-B1 | CANNABIS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN AND INFLAMMATION RELATED WITH DENTAL PULP AND BONE REGENERATION RELATED TO DENTAL JAW BONE DEFECTS | CANNIBITE BVBA (BE) | 2024-06-19 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2023114529-A2 | PHARMACOACTIVE FORMULATIONS FOR DELIVERY OF PSYCHEDELIC COMPOUNDS | BENNES, INC. (US) | 2023-06-22 | — | — | WO | claimed |
| WO-2023064477-A1 | COMPOSITIONS FOR DELIVERY OF CANNABINOIDS | PNEUMA RESPIRATORY, INC. (US) | 2023-04-20 | — | — | WO | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| US-20220387376-A1 | Compositions Comprising Cannabinoid Molecules that are Dissolved in Water-Miscible Solvents | NATURAL EXTRACTION SYS LLC (US) | 2022-12-08 | — | — | US | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022026960-A1 | COMPOSITIONS AND METHODS RELATED TO EXCIPIENTS AND CANNABINOID FORMULATIONS | Natural Extraction Systems, LLC (US) | 2022-02-03 | — | — | WO | claimed |
| WO-2021042001-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | Natural Extraction Systems, LLC (US) | 2021-03-04 | — | — | WO | claimed |
| US-20200222361-A1 | Cannabis and Derivatives Thereof for the Treatment of Pain and Inflammation Related with Dental Pulp and Bone Regeneration Related to Dental Jaw Bone Defects | CANNIBITE BVBA (BE) | 2020-07-16 | — | — | US | claimed |
| EP-3664795-A2 | CANNABIS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN AND INFLAMMATION RELATED WITH DENTAL PULP AND BONE REGENERATION RELATED TO DENTAL JAW BONE DEFECTS | Cannibite BVBA (BE) | 2020-06-17 | — | — | EP | claimed |
| WO-2019030762-A2 | CANNABIS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN AND INFLAMMATION RELATED WITH DENTAL PULP AND BONE REGENERATION RELATED TO DENTAL JAW BONE DEFECTS | STAHL VERONICA (BE) | 2019-02-14 | — | — | WO | claimed |
| WO-2018145219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING | SERANI MOSTAZAL JORGE (CL) | 2018-08-16 | — | — | WO | claimed |
| WO-2014153099-A2 | METHOD FOR USING EXHALED BREATH TO DETERMINE THE PRESENCE OF DRUG | Pulmonary Analytics (US) | 2014-09-25 | — | — | WO | claimed |
| US-20140288454-A1 | Method For Using Exhaled Breath to Determine the Presence of Drug | Pulmonary Analytics (US) | 2014-09-25 | — | — | US | claimed |
| US-20050014838-A1 | Method for treating vasculature degeneration and stimulating glucose | GREYSTONE MEDICAL GROUP, INC. | 2005-01-20 | — | — | US | claimed |
| WO-2005002528-A2 | METHOD FOR TREATING DIABETES | GREYSTONE MEDICAL GROUP, INC. (US) | 2005-01-13 | — | — | WO | claimed |
| US-6328992-B1 | Cannabinoid patch and method for cannabis transdermal delivery | PATCHTEK INC. | 2001-12-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387376-A1 | Compositions Comprising Cannabinoid Molecules that are Dissolved in Water-Miscible Solvents | CNR2, CNR1, PHOSPHO1 | CNR2 1/4885CNR1 2/4885MEN1 2631/4885 |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | CNR2 3068/4885CNR1 3464/4885MEN1 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.